ROSSARI BIOTECH LIMITED
₹399.25-₹8.20 (-2.0%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹3,016 Cr
- P/E
- 25.0x
- EV / EBITDA
- 17.7x
- Revenue
- ₹1,432 Cr
- Net margin
- 8.3%
- ROCE
- 15.7%
Price chart
Technical chartScreen technicals →-37.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -4.3%
- 3M
- -21.4%
- 6M
- -16.6%
- 1Y
- -37.9%
- 5Y
- -70.7%
52-week range
Day change -₹8.20 (-2.0%) from ₹407 to ₹399 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ROSSARI, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Revenue grew 19.0% YoY
Concerns0
Rule-based from financial data. Not advice.
About the company
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions.
Read moreShow less
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, India.
- Sector
- Technology
- Shares outstanding
- 5.5 Cr shares
- ISIN
- INE02A801020
- BSE code
- 543213
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹3,016 Cr
- P/E
- 25.0x
- P/B
- 2.7x
- EV / EBITDA
- 17.7x
- EV / Sales
- 2.5x
- P/S
- 2.5x
- Earnings yield
- 4.0%
- 52-week high
- ₹673.05
- 52-week low
- ₹378.30
Profitability
- Operating margin
- 13.4%
- Net margin
- 8.3%
- EBITDA margin
- 14.0%
- ROE
- 10.4%
- ROCE
- 15.7%
- ROA
- 7.8%
- Dividend payout
- 3.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 5.2%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,432 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.9%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹168 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 32.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.0%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹74.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -34.5%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹10.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.8%
Solvency and efficiency
- Current ratio
- 4.30
- Debt / Equity
- 0.07
- Debt / Assets
- 0.05
- Debt / EBITDA
- 0.40
- Interest coverage
- 16.10
- Financial leverage
- 1.33
- CFO / Net profit
- 0.74
- Cash / Market cap
- 18.6%
- Cash per share
- ₹101.37
- Asset turnover
- 0.94
- Fixed asset turnover
- 7.20
- Capital intensity
- 0.14
- Debtor days
- 92 days
- Inventory turnover
- 5.98
- Cash conversion cycle
- 61 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹1,432 Cr |
| Expenses | ₹1,245 Cr |
| Operating profit | ₹186 Cr |
| Other income | ₹6 Cr |
| Interest | ₹10 Cr |
| Depreciation | ₹28 Cr |
| Profit before tax | ₹155 Cr |
| Tax and other | ₹40 Cr |
| Net profit | ₹115 Cr |
Revenue and net profit
Revenue grew 19.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹690 Cr | ₹79 Cr |
| FY2022 | ₹1,073 Cr | ₹79 Cr |
| FY2023 | ₹975 Cr | ₹71 Cr |
| FY2024 | ₹1,203 Cr | ₹100 Cr |
| FY2025 | ₹1,432 Cr | ₹115 Cr |
Cash flows
FY2025: ₹92.0 Cr from operations, ₹22.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹52 Cr | ₹15 Cr |
| FY2022 | ₹33 Cr | -₹285 Cr |
| FY2023 | ₹113 Cr | -₹47 Cr |
| FY2024 | ₹74 Cr | ₹4 Cr |
| FY2025 | ₹92 Cr | ₹22 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,432 Cr+19.0%1Y
- Net profit
- ₹115 Cr+15.0%1Y
- Cash from operations
- ₹92 Cr
- Free cash flow
- ₹22 Cr+450.0%1Y
- Revenue CAGR, 5Y
- 14.9%
- EBITDA CAGR, 5Y
- 9.0%
- Net profit CAGR, 5Y
- 8.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,432 Cr | ₹186 Cr | — | ₹115 Cr | ₹92 Cr | ₹22 Cr | 10.7% | +19.0% | +15.0% |
Monthly returns
Month-by-month returns of ROSSARI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,451 Cr |
| Equity capital | ₹11 Cr |
| Reserves | ₹1,066 Cr |
| Borrowings | ₹50 Cr |
| Other liabilities | ₹324 Cr |
| Assets | ₹1,451 Cr |
| Fixed assets | ₹179 Cr |
| Capital work in progress | ₹34 Cr |
| Investments | ₹538 Cr |
| Other assets | ₹699 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ROSSARI trades at 25.0x earnings against a peer median of 52.1x (a 52% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ROSSARI BIOTECH LIMITEDROSSARIthis companyP/E ↓ discount | ₹3,016 Cr | 25.0x | 2.7x | 10.4% | 17.7x |
| MOSCHIP TECHNOLOGIES LIMITEDMOSCHIP | ₹3,729 Cr | 95.8x | 10.2x | 2.2% | 163.7x |
| Shilchar Technologies Ltd.SHILCTECH | ₹3,663 Cr | 20.6x | 8.7x | 43.8% | 28.7x |
| Sandhar Technologies LimitedSANDHAR | ₹3,369 Cr | 19.2x | 2.7x | 10.9% | 13.3x |
| Advanced Enzyme Technologies LimitedADVENZYMES | ₹3,248 Cr | 26.5x | 4.8x | 18.6% | 22.1x |
| 63 Moons Technologies Limited63MOONS | ₹3,203 Cr | 83.9x | 1.1x | 9.4% | 10.1x |
| Cyient DLM LimitedCYIENTDLM | ₹3,173 Cr | 42.1x | 3.3x | 6.7% | 22.3x |
| Protean eGov Technologies LimitedPROTEAN | ₹2,888 Cr | 30.5x | 2.8x | 10.8% | 17.5x |
| Network People Services Technologies LimitedNPST | ₹2,762 Cr | 97.8x | 6.6x | 47.4% | 59.8x |
| Peer median | — | 52.1x | 7.8x | 14.5% | 34.2x |
Year-to-date ROI
ROSSARI since 1 January, against earlier years.
Historical volatility
ROSSARI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 18.0% |
| FY2022 | 11.0% |
| FY2023 | 13.0% |
| FY2024 | 13.0% |
| FY2025 | 13.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,432 Cr |
| Costs | |
| Interest | ₹10 Cr |
| Expenses | ₹1,245 Cr |
| Operating profitOperating Profit | ₹186 Cr |
| Other income and charges | |
| Profit before tax | ₹155 Cr |
| Tax | |
| Net profitNet Profit | ₹115 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,451 Cr |
| Equity capitalEquity Capital | ₹11 Cr |
| Reserves | ₹1,066 Cr |
| Borrowings | ₹50 Cr |
| Other liabilitiesOther Liabilities | ₹324 Cr |
| AssetsTotal Assets | ₹1,451 Cr |
| Fixed assetsFixed Assets | ₹179 Cr |
| Capital work in progressCWIP | ₹34 Cr |
| Investments | ₹538 Cr |
| Other assetsOther Assets | ₹699 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹92 Cr |
| Investing cash flowCash from Investing Activity | -₹70 Cr |
| Financing cash flowCash from Financing Activity | -₹32 Cr |
| Change in cashNet Cash Flow | -₹10 Cr |
Learn while you research
Academy chapters picked for ROSSARI BIOTECH LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Growth InvestingTech & communications often trade on growth, learn the framework.7 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read